Navigation Links
CEL-SCI Presents Long-Term Cancer Survival Data With Multikine

(FDA) to proceed to a Phase III clinical trial with Multikine earlier this year. The same treatment regimen that was used in CEL-SCI's final Phase II trial will be used in the upcoming Phase III trial that CEL-SCI will undertake since the results obtained in the final Phase II trial are thought to be indicative of the results one might expect in any Phase III trial of Multikine. The Phase III trial is designed to demonstrate a 10% increase in overall survival of patients treated with adjuvant Multikine therapy versus those treated only with the current standard of care.

Dr. Talor said, "Having shown a 33% increase in overall survival with no safety concerns in the final Phase II study, we are very hopeful that we will successfully reach the 10% increase in overall survival that is the primary endpoint of our Phase III trial. To further enhance the probability of meeting our primary endpoint, we are over-enrolling the study."

Documented data were available for 19 of the 22 patients in the follow-up portion of this clinical trial. Of the three patients who could not be evaluated in the follow-up study, one patient was known to be alive, but failed to give informed consent, and the other two were lost to follow-up. One patient died the day after definitive surgery, unrelated to Multikine therapy.

Head & neck cancer is an aggressive cancer that affects over 500,000 - 600,000 people per annum worldwide.

CEL-SCI Corporation is developing new immune system based treatments for cancer and infectious diseases. The Company has received the go-ahead from the U.S. FDA and the Canadian Regulators to conduct a Phase III clinical trial in advanced primary head and neck cancer patients with its lead product Multikine. CEL-SCI's other products, which are currently in pre-clinical stage and have been funded with U.S. government support, have shown protection against a number of diseases in animal tests and are currently being tested against diseases a
'"/>




Page: 1 2 3

Related medicine technology :

1. CEL-SCIS CEL-1000 Shown to Significantly Enhance Immune Response Against Avian Flu Antigen in Animals
2. CEL-SCIs Cel-1000 Shown to Significantly Enhance Immune Response Against Hepatitis B Antigen in Animals
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
5. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
6. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
7. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
8. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
9. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
10. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
11. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: CEL SCI Presents Long Term Cancer Survival Data With Multikine
(Date:11/20/2009)... Nov. 20 Reportlinker.com announce...n its catalogue. ,, Medical Adhesives and Seal...rtlinker.com/p0164242/Medical-Adhesives-and-Sealan...&utm_medium=pr&utm_campaign=prnewswire ,...gaining preeminence in medical devices and equipme...
(Date:11/20/2009)..., N.J., Nov. 20 BD (Bect...nounced the completion of its acquisition of Handy...at develops and manufactures molecular diagnostic ..., BD and HandyLab announced an exclusive agreement...ays on the HandyLab Jaguar(TM) platform, the first...
(Date:11/19/2009)...Nov. 19 In response to an ever-inc... illegal medicines, Operation Pangea II, involving... World Health Organization,s International Medical...o highlight the dangers of buying medicines online...n a series of arrests and the seizure of thousands...
Breaking Medicine Technology:Reportlinker Adds Medical Adhesives and Sealants - A US Market Review 2Reportlinker Adds Medical Adhesives and Sealants - A US Market Review 3Reportlinker Adds Medical Adhesives and Sealants - A US Market Review 4Reportlinker Adds Medical Adhesives and Sealants - A US Market Review 5Reportlinker Adds Medical Adhesives and Sealants - A US Market Review 6BD Completes Acquisition of HandyLab, Inc. 2BD Completes Acquisition of HandyLab, Inc. 3International Operation Combats Online Supply of Counterfeit and Illegal Medicines 2Announcing Sustainability in Packaging 2010 3A Strategies to make sustainability sustainable 13946 1Announcing Sustainability in Packaging 2010 3A Strategies to make sustainability sustainable 13946 2Announcing Sustainability in Packaging 2010 3A Strategies to make sustainability sustainable 13946 3First Cape Cod Macular Degeneration Symposium To Be Held on September 17 56628 1First Cape Cod Macular Degeneration Symposium To Be Held on September 17 56628 2First Cape Cod Macular Degeneration Symposium To Be Held on September 17 56628 3Michigan Pre Seed Capital Fund Awards Three Micro Loans 13945 1Michigan Pre Seed Capital Fund Awards Three Micro Loans 13945 2
...Nova BioSciences, Inc.,("CeloNova"), leading and a...sion and development of innovative medical devices... 8 country European study of uterine fibroid,embol...res. The study,results were reported at the 20th A...apy., (Photo: http://www.newscom.com/cgi-bin/prn...
...on for HUMIRA Provides Patients with Visible, Cle...Autoimmune Disease, ABBOTT PARK, Ill., Jan. 18 A...d U.S. Food and Drug Administration (FDA),approval...or adult patients,with moderate to severe chronic ...zed by skin lesions that are sometimes painful and...
Other Medicine Technology:CeloNova BioSciences Announces Positive Results from European Study of Embozene(TM) Microspheres for Treatment of Uterine Fibroids 2Abbott's HUMIRA(R) (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis 2Abbott's HUMIRA(R) (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis 3Abbott's HUMIRA(R) (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis 4Abbott's HUMIRA(R) (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis 5Abbott's HUMIRA(R) (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis 6Abbott's HUMIRA(R) (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis 7
(Date:11/20/2009)...od pressure readings in children with chronic kidn... during doctor,s office visits increasing a child...esearch from Johns Hopkins Children,s Center and o...s online in the Journal of American Society of Nep... measurements obtained during regular doctor visit...
(Date:11/20/2009)...nks it,s as short as 34 weeks, potentially adding ..., FRIDAY, Nov. 20 (HealthDay News) -- Recent repor...ues to climb in the United States. Now, a new stu...d about what constitutes a full-term birth in the ... surveyed in the study considered a baby born at 3...
(Date:11/20/2009)...ctivity remains high and is expected to continue, ...y News) -- Some areas of the United States are see... health official said Friday, and while the diseas...m the 46 states reported last week. , "We are b...y around the country, but there is still a lot of ...
(Date:11/20/2009)... SPRINGFIELD, Mo., Nov. 20 Missour...al Missouri regions will now have the option to ch...ched Tuesday between Missouri Consolidated Health ...e Southwest and South Central Missouri regions inc... Christian, Dade, Dallas, Douglas, Greene, Hickory...
(Date:11/20/2009)... BATON ROUGE, La., Nov. 20 /PRNewswire-USNewswir...(LAHP) today warned that Louisianians could experi...its if proposals being considered by Congress shou... executive officer for LAHP, "Louisiana health pla... since the beginning of the national debate. Our ...
Breaking Medicine News(10 mins):Health News:High blood pressure easy to miss in children with kidney disease 2Health News:Many Women Miscalculate Time to Full-Term Birth 2Health News:Many Women Miscalculate Time to Full-Term Birth 3Health News:Many Women Miscalculate Time to Full-Term Birth 4Health News:Swine Flu Declining in Some Parts of U.S. 2Health News:Swine Flu Declining in Some Parts of U.S. 3Health News:Missouri Consolidated Health Care Plan Provides Mercy Health Plans Option 2Health News:Congressional Health Care Reform Proposals Would Make Health Care More Expensive, Reduce Benefits for Louisianians 2
...7 Merck & Co., Inc.,today said that it has not ye...k State and New York City seeking Medicaid reimbur...t the suit as it has defended against the,Medicaid...ug Administration (FDA) approval, and consistently...
...or Living,Inc. (NYSE: BKD ) announced today that ...sh dividend on its common stock of $0.50 per share....50 per share dividend is payable,on October 12, 2...ving facilities throughout the United States. The ...
...Biosciences,Inc. (LSE: AKR) which develops, manufa...g and testing products, is pleased to announce tha...Army for the purchase of its,BreathScan alcohol sa...gnificant,orders from several departments of the U...
... Focus on Cardiovascular Disease, Prevention and ...e Care Improvements, ...Charlie,Rose Science Series" on PBS will focus on ...l Laureate and President of,Rockefeller University...
...hat patients with cancer in the head and neck regi...kills compared with individuals without the diseas... Archives of Otolaryngology-Head & Neck Surgery, o...ork together. These functions can be compromised t...
...rday, October 20,Event to be held in honor of Octo...PLAINS, Mo., Sept. 17 GAMMILL QUILTING SYSTEMS, a...ngarm quilting systems, in,cooperation with it,s n...tional Breast Cancer Awareness Month; and in,suppo...
Other Medicine News:Health News:Merck & Co., Inc. Response to Today's New York Medicaid Suit 2Health News:Merck & Co., Inc. Response to Today's New York Medicaid Suit 3Health News:Akers Biosciences, Inc. 'ABI' or the 'Company' Receipt of Further United States Military Contracts 2Health News:Charlie Rose Science Series Explores Heart Disease 2Health News:Charlie Rose Science Series Explores Heart Disease 3Health News:Patients with head and neck cancer may have impairment of some driving skills 2Health News:'Think Pink with Gammill(R)' 2
...ional reference laboratory and a worldwide leader ... ARUP offers an extensive test menu of highly comp...mic pathology. Owned by the University of Utah, AR... the nation's university teaching hospitals and ch...
...ional reference laboratory and a worldwide leader ... ARUP offers an extensive test menu of highly comp...mic pathology. Owned by the University of Utah, AR... the nation's university teaching hospitals and ch...
...ional reference laboratory and a worldwide leader ... ARUP offers an extensive test menu of highly comp...mic pathology. Owned by the University of Utah, AR... the nation's university teaching hospitals and ch...
...ional reference laboratory and a worldwide leader ... ARUP offers an extensive test menu of highly comp...mic pathology. Owned by the University of Utah, AR... the nation's university teaching hospitals and ch...
Medicine Products: